FMI Immune Checkpoint Inhibitors Market Value Share, A | страница 5

Immune Checkpoint Inhibitors Market
Immune Checkpoint Inhibitors Market: Overview
The immune checkpoint inhibitor market is driven by the need to address the rising rate of cancer
prevalence thereby affecting the country healthcare cost. In UK, lung cancer is the leading cause of
cancer related death. The survival rate past five years has only being 9% after the person is diagnosed
with lung cancer. The new form of immunotherapy based on the inhibition of programmed death-ligand 1
(PD-L1) and programmed death-1 (PD-1) receptors has shown hope as a therapy option for lung cancer.
Immune Checkpoint Inhibitors Market: Region-wise Outlook
In terms of geography, immune checkpoint inhibitors market has been divided into five regions including
North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. The number of clinical
trials and research funding is relatively high in North America, making it the dominant region in terms of
revenue in the immune checkpoint inhibitors market. In September 2014, Merck received accelerated
FDA approval for its Keytruda molecule to treat patient with advanced melanoma. The company is
forming global alliances with other companies to co-develop
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3326
immnuo-oncology research and expand its oncology business.
©2015 Future Market Insights, All Rights Reserved
5